No­var­tis' San­doz chief is walk­ing out in the mid­dle of a glob­al re­vamp, fu­el­ing fresh buzz about a spin­off

The head of No­var­tis’ big gener­ics di­vi­sion San­doz has abrupt­ly hand­ed in his walk­ing pa­pers in a move that will im­me­di­ate­ly reignite spec­u­la­tion that CEO Vas Narasimhan may be prep­ping a spin­off plan for the strug­gling group as the par­ent or­ga­ni­za­tion con­cen­trates on de­vel­op­ing new drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER